Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise
Nucor (NYSE: NUE) isn’t just another steelmaker churning out metal for skyscrapers and rebar. It’s a powerhouse that has weathered economic storms, steel cycles, and shifting energy costs, all while steadily raising its dividend for over the past half century.
Yet, despite that remarkable consistency, investors seems to be snoozing on Nucor right now so is it time to buy?
» Read more about: Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise »
Read More
Will This Tiny Quantum Stock 2x by 2030?
IonQ isn’t a household name yet. But give it time. This small-cap quantum computing company is pulling in some big-league attention and the numbers from early 2025 are starting to back it up.
You’re probably used to hearing about quantum computing like it’s some distant dream but in Q1 2025, that revenue hit $7.6 million.
» Read more about: Will This Tiny Quantum Stock 2x by 2030? »
Read More
Billionaire Loves These Stocks Most of All
Stanley Druckenmiller doesn’t toss around stock picks like confetti. When he makes a move, it matters not just because of his track record (which is ridiculous by the way) but because his strategy blends macro trends with razor-sharp stock selection.
In 2025, he’s not chasing headlines. He’s making some bold, high-conviction bets, and a few of them are pretty surprising.
» Read more about: Billionaire Loves These Stocks Most of All »
Read More
Is This The Most Bullish Signal Wall Street Has Ever Flashed?
In April, we witnessed something remarkable. The S&P 500 had one of its sharpest two-day drops in the last three quarters of a century, only to turn around and post its largest single-day point gain in history.
On a single trading day, all three major indexes the Dow, S&P 500, and Nasdaq booked their biggest-ever nominal advances.
» Read more about: Is This The Most Bullish Signal Wall Street Has Ever Flashed? »
Read More
4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read MoreThe Burst
1 Sleep-Well-at-Night Stock That Sends You a Check Every Month
Nicknamed “The Monthly Dividend Company,” Realty Income isn’t your average real estate play. It’s one of the few publicly traded companies that sends a dividend check every single month, and it’s done so like clockwork for more over 600 consecutive months.
Its current forward yield sits at precisely 5.60%, a hefty figure in today’s environment.
» Read more about: 1 Sleep-Well-at-Night Stock That Sends You a Check Every Month »
Read MoreThe Spotlight
Is Target Stock a Hidden Gem for Patient Value Investors?
Target (NYSE: TGT) hasn’t had the best run lately. In fact, shares have slid 29.9% so far this year, a sharp contrast to the broader market, with the S&P 500 flat on the year. It’s a tough pill to swallow, especially when you consider Target was already on the back foot coming into 2025.
But here’s the twist,
» Read more about: Is Target Stock a Hidden Gem for Patient Value Investors? »
Read MoreThe Daily
Ahead of Fed Chair Powell’s Jackson Hole speech, data suggests cracks in US economy
For three days starting Thursday, some of the biggest names in the world of finance and economics will gather in Wyoming, US for the most hotly-watched central banking conference. Organised by the Federal Reserve Bank of Kansas City, the Jackson Hole Economic Policy Symposium has become a crucial policy event ever since it was first held in 1978 in Kansas City.